Abstract

Abstract Multidrug resistance (MDR) remains is a major hurdle to overcome in cancer therapy. Enhanced cell proliferation and survival of cancerous cells in solid tumor environment along with survival of stem cells to repopulate the tumor and metastasis complicate the matter even more. Therefore, retardation of cell growth and/or induction of apoptosis by posttranscriptional silencing based on short interfering RNA (siRNA) is promising, but remains challenging due to inability of anionic siRNA to cross cell membrane. We previously reported the safety and efficiency of lipid substitution on small molecular weight, non-toxic polyethylenimine (PEI) as promising approach for siRNA delivery. In this study, we report silencing of myeloid cell leukemia 1 (MCL-1) both as an individual target to induce apoptosis and incorporated in multiple silencing in wild type (WT) MDA-MB-435 human breast cancer cells, as well as cells rendered resistant as a result of exposure to an anticancer agent and MDR version of the same cells. Down-regulation of P-glycoprotein (P-gp), survivin, and MCL-1 with respective siRNAs were studied individually and in combinations. While silencing MCL-1 caused almost 90% cell death in the WT cells, the effect was less significant in the MDR cells. Silencing both MCL-1 and P-gp in the MDR cells showed a synergistic effect. Resistance induction, as confirmed by both IC50 experiments and doxorubicin (DOX) uptake, caused an up-regulation in the expression of not only P-gp, but also BCRP, survivin, and MCL-1. Our double silencing experiments in resistance-induced cells showed a similar pattern to MDR cells; however, in the later stages of resistance induction, prolonged exposure to higher DOX concentrations caused a cell dependency on MCL-1 and a cross-link between MCL-1 and P-gp. MCL-1 silencing was proven to be more efficient in causing cell death in resistance-induced cells compared to MDR cells. A re-sensitization to cytotoxic effect of DOX was observed in resistance-induced cells after silencing of MCL-1. In addition to confirming MCL-1 as a viable target for siRNA silencing, this study indicates that anti-apoptotic proteins such as survivin and MCL-1 may have a role in resistance that could be closely related to efflux proteins.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.